These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8951689)

  • 1. Biotransformation in review: applications in ocular disease and drug design.
    Gaynes BI; Fiscella RG
    J Ocul Pharmacol Ther; 1996; 12(4):527-39. PubMed ID: 8951689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming ocular drug delivery barriers through the use of physical forces.
    Huang D; Chen YS; Rupenthal ID
    Adv Drug Deliv Rev; 2018 Feb; 126():96-112. PubMed ID: 28916492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liver and metabolism of drugs].
    Darnis F
    Cah Med; 1974 Oct; 15(10):637-43. PubMed ID: 4455367
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of pharmacologically active metabolites in drug discovery and development.
    Fura A
    Drug Discov Today; 2006 Feb; 11(3-4):133-42. PubMed ID: 16533711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.
    White RE
    Annu Rev Pharmacol Toxicol; 2000; 40():133-57. PubMed ID: 10836130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioactivation of drugs: risk and drug design.
    Walsh JS; Miwa GT
    Annu Rev Pharmacol Toxicol; 2011; 51():145-67. PubMed ID: 21210745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe prescribing in liver disease.
    Br Med J; 1973 Apr; 2(5860):193-4. PubMed ID: 4700003
    [No Abstract]   [Full Text] [Related]  

  • 9. Practical pharmacokinetics as part of clinical pharmacology.
    Gladtke E
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):37-41. PubMed ID: 4924326
    [No Abstract]   [Full Text] [Related]  

  • 10. Chirality in new drug development. Clinical pharmacokinetic considerations.
    Nation RL
    Clin Pharmacokinet; 1994 Oct; 27(4):249-55. PubMed ID: 7834962
    [No Abstract]   [Full Text] [Related]  

  • 11. Adaptive responses of the liver to foreign compounds, with special reference to microsomal drug-matabolizing enzymes.
    Wada O; Yano Y
    Rev Environ Health; 1974; 1(4):261-82. PubMed ID: 4617260
    [No Abstract]   [Full Text] [Related]  

  • 12. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
    Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of hepatic metabolism on the production and toxicity of reactive metabolites in extrahepatic organs.
    Boyd MR; Statham CN
    Drug Metab Rev; 1983; 14(1):35-47. PubMed ID: 6839941
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.
    Fura A; Shu YZ; Zhu M; Hanson RL; Roongta V; Humphreys WG
    J Med Chem; 2004 Aug; 47(18):4339-51. PubMed ID: 15317447
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinico-pharmacological aspects of enzyme induction].
    Bartłomowicz B
    Pol Tyg Lek; 1985 Dec 23-30; 40(51-52):1430-3. PubMed ID: 3913943
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity.
    Murphy CD; Sandford G
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):589-99. PubMed ID: 25728479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatic enzyme induction and drug effects].
    Paumgartner G
    Ther Umsch; 1971 Apr; 28(4):234-40. PubMed ID: 5575081
    [No Abstract]   [Full Text] [Related]  

  • 18. Minimizing the potential for metabolic activation as an integral part of drug design.
    Evans DC; Baillie TA
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug metabolism in birds.
    Pan GP; Fouts JR
    Drug Metab Rev; 1978; 7(1):1-253. PubMed ID: 350533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.